Direvo Biotech has announced that it has raised €10.5m (US$) in its Series B equity financing.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Direvo describes itself as a leading company in screening-based directed evolution, applying its integrated proprietary technologies to the development of better biopharmaceuticals, industrial enzymes, chemical biocatalysts and enzymes for food and feed. The company was established in the year 2000 and collaborates with companies such as Danisco, Novozymes and Evotec OAI.
With Danisco Venture, Copenhagen, as lead investor and TVM (Techno Venture Management), Munich, as co-lead investor, the Cologne-based German biotechnology company Direvo Biotech has raised €10.5m in new equity capital in its Series B financing.
Further investors in this round are SK Kapitalbeteiligungsgesellschaft Köln, New York based Sanders Morris Harris and the private investors Nobel laureate Prof. Manfred Eigen, Dr Ruthild Winkler-Oswatitsch, Prof. Heinrich M. Schulte as well as all other investors from the Series A financing.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
